Recently, Yu et al. reported that suppression of ERBB2 (Erb-B2 Receptor Tyrosine Kinase 2) was observed with the negative regulatory activity on MAPK1/MAPK3 signaling pathway that led to the hinderance of tumor progression in ovarian cancer cells (47). This evidence concerns the gene MAPK3 and neoplasm.